Fig. 2: MSCs reduce intracellular mutant protein ataxin-3 levels in SCA3 patients. | Cell Death & Disease

Fig. 2: MSCs reduce intracellular mutant protein ataxin-3 levels in SCA3 patients.

From: Transcription factor EB-mediated mesenchymal stem cell therapy induces autophagy and alleviates spinocerebellar ataxia type 3 defects in neuronal cells model

Fig. 2: MSCs reduce intracellular mutant protein ataxin-3 levels in SCA3 patients.

A Westen blotting detection of autophagy-related proteins in Control and SCA3 groups. B Detection of p62, Beclin1, ULK1, and LC3 at different treatment times after MSCs-SCA3 patient co-culture for 1 h. C Time-dependent expression of mutant ataxin-3 after MSCs therapy for 72 h. D The effects of GW4869 on the expression of p62, Beclin1, LC3, ULK1, and ataxin-3. E The effects of 3-MA and CQ on the expression of p62, Beclin1, LC3, ULK1, and ataxin-3 after MSCs therapy. F LC3 and Lamp1 co-localization after MSCs by immunofluorescence (scale bar: 50 μm). G DAPI and mutant ataxin-3 co-localization after MSCs by immunofluorescence (scale bar: 50 μm). H Acidic vesicles induced by MSCs treatment using acridine orange staining (scale bar: 50 μm). *p < 0.05, **p < 0.01, ***p < 0.001 vs Control group, #p < 0.05, ##p < 0.01, ###p < 0.001.

Back to article page